-
Human medicines European public assessment report (EPAR): Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma), dabigatran etexilate, Date of authorisation: 19/02/2024, Revision: 5, Status: Authorised
21 Jan 2025 22:14 GMT
… occurring again.
Dabigatran etexilate Teva contains the active substance dabigatran etexilate.
Dabigatran etexilate Teva is … of medicine
Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)
Active substance
Dabigatran etexilate mesilate
…
-
Human medicines European public assessment report (EPAR): Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma), dabigatran etexilate, Date of authorisation: 19/02/2024, Revision: 3, Status: Authorised
26 Sep 2024 19:45 GMT
… again.
Dabigatran etexilate Leon Farma contains the active substance dabigatran etexilate.
Dabigatran etexilate Leon Farma … of medicine
Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)
Active substance
Dabigatran etexilate mesilate
…
-
Alembic Pharma secures USFDA approval for Dabigatran Etexilate Capsules
13 Aug 2024 08:03 GMT
… Abbreviated New Drug Application (ANDA) Dabigatran Etexilate Capsules, 110 mg.
The … of Boehringer Ingelheim Pharmaceuticals, Inc.
Dabigatran Etexilate Capsules 110 mg are indicated … stroke and blood clots drug Dabigatran Etexilate
Alembic has a cumulative …
-
Alembic Pharma receives USFDA approval for Dabigatran Etexilate Capsules
13 Aug 2024 07:29 GMT
… Abbreviated New Drug Application (ANDA) Dabigatran Etexilate Capsules, 110 mg. The approved … Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer).
Dabigatran Etexilate Capsules 110 mg are indicated …
-
Human medicines European public assessment report (EPAR): Dabigatran etexilate Teva , dabigatran etexilate, Status: Withdrawn application (after opinion)
28 Jun 2024 12:53 GMT
… its provisional opinion was that Dabigatran etexilate Teva could not have been … was that the benefits of Dabigatran etexilate Teva did not outweigh its …
-
Alembic Pharmaceuticals receives USFDA approval for Dabigatran Etexilate Capsules
18 Jun 2024 14:04 GMT
… Drug Application (ANDA) for Dabigatran Etexilate Capsules, 75 mg and 150 … mg and Tentative approval for Dabigatran Etexilate Capsules, 110 mg. The … Ingelheim Pharmaceuticals, Inc. (Boehringer).
Dabigatran Etexilate Capsules are indicated for reduction …
-
Alembic Pharmaceuticals receives US FDA approval for Dabigatran Etexilate capsules, 75 mg, 150 mg
18 Jun 2024 13:09 GMT
… new drug application (ANDA) for Dabigatran Etexilate Capsules, 75 mg and 150 … mg and tentative approval for Dabigatran Etexilate Capsules, 110 mg.
The approved … of Boehringer Ingelheim Pharmaceuticals, Inc. Dabigatran Etexilate capsules are indicated for the …
-
Alembic Pharma gets USFDA nod for Dabigatran Etexilate capsules
18 Jun 2024 10:47 GMT
… New Drug Application (ANDA) for Dabigatran Etexilate capsules 110 mg, Alembic Pharmaceuticals … Inc. (Boehringer), it added.
The Dabigatran Etexilate capsules are indicated for the … patients.
Alembic Pharma said Dabigatran Etexilate capsules 75 mg and 150 …
-
Alembic Pharmaceuticals announces USFDA Final Approval for Dabigatran Etexilate Capsules, 75 mg and 150 mg and Tentative approval for Dabigatran Etexilate Capsules, 110 mg
18 Jun 2024 09:54 GMT
… Drug Application (ANDA) for Dabigatran Etexilate Capsules, 75 mg and 150 … mg and Tentative approval for Dabigatran Etexilate Capsules, 110 mg. The … Ingelheim Pharmaceuticals, Inc. (Boehringer). Dabigatran Etexilate Capsules are indicated for reduction …
-
Medication Administration Through Feeding Tubes in a Tertiary Hospital: A Retrospective Observational Study
01 Feb 2025 10:18 GMT
… , glimepiride tablets, carbamazepine tablets, and dabigatran etexilate capsules that were inappropriately administered …
About
© 1995-2025